Clinical Trial Update: Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on tivantinib for pediatric relapsed/refractory solid tumors. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Solid Neoplasm | Phase 1 | Status: COMPLETED